Summary
Pfizer Inc. (PFE) filed an 8-K on May 3, 2016, to report its financial results for the first quarter of 2016. The filing primarily consists of furnishing a press release that details these results. Investors should note that the information provided in this 8-K, including the attached press release, is furnished and not deemed 'filed' under Section 18 of the Exchange Act, meaning it does not carry the same legal liabilities. This is a common practice for disseminating earnings information without triggering specific filing requirements.
Key Highlights
- 1Pfizer announced its first-quarter 2016 financial results on May 3, 2016.
- 2The 8-K filing includes a press release detailing the Q1 2016 financial performance.
- 3The press release (Exhibit 99) is furnished, not filed, with the SEC.
- 4Information furnished under Item 2.02 is generally not subject to Section 18 of the Exchange Act liabilities.
- 5The filing's primary purpose is to make the Q1 2016 earnings announcement publicly available through SEC channels.
Frequently Asked Questions
The main purpose of this 8-K filing is to officially report and make publicly available Pfizer's financial results for the first quarter of 2016, as announced in their press release dated May 3, 2016.
The financial information furnished in this 8-K, including the press release, is not considered 'filed' under Section 18 of the Securities Exchange Act of 1934. This means it does not carry the same level of legal liability as information formally filed with the SEC.
The detailed financial results for the first quarter of 2016 are provided in the press release (Exhibit 99) that is furnished as part of this 8-K filing.
This specific 8-K filing is focused solely on the dissemination of first-quarter 2016 financial results. It does not detail new business developments or strategic changes beyond what might be included in the earnings press release itself.